Logo

SeraCare Licenses Genetic Testing Controls for CF

Oct 30, 2008
NEW YORK (GenomeWeb News) – SeraCare Life Sciences today said that it has licensed from Sacred Heart Medical Center & Children’s Hospital in Spokane, Wash., exclusive rights to controls for genetic testing including screening for cystic fibrosis and for diseases common among Ashkenazi Jews.
 
The Milford, Mass.-based firm announced the licensing deal concurrent with the launch of its new genetic testing controls business line. This business line initially includes controls for warfarin sensitivity testing and thrombophilia testing, which were developed internally by SeraCare.
 
“In the coming months, we will continue to make key additions to the genetic controls product portfolio as this business line plays an important role in the company’s near-term growth strategy and future profitability,” SeraCare President and CEO Susan Vogt said in a statement.

Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.